Time called on Pfizer–AstraZeneca deal


Pfizer’s pursuit of a pharmaceutical megamerger with AstraZeneca (AZ) has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK’s takeover rules.

The City Code on Takeovers and Mergers allows Pfizer to make a new approach to AZ after a six month cooling off period, or AZ can invite Pfizer to negotiate after three months. Given the Anglo-Swedish firm’s steadfast refusal to entertain Pfizer’s advances, the latter option seems unlikely. ‘We welcome the opportunity to continue building on the momentum we have already demonstrated as an independent company,’ AZ’s chairman Leif Johansson said in a statement after the withdrawal.

Pfizer, in its turn, is leaving the door open. ‘We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us’ said chief executive Ian Read in the withdrawal statement. The value and attactiveness of any new offer will depend strongly on how well AZ lives up to predictions about forthcoming drugs made by the board to justify its refusal of this deal. 


Related Content

Pfizer presses hard for AstraZeneca deal

14 May 2014 Business

news image

Executives face down international controversy over tax schemes and previous post-merger record

Hospira buyout is a shot in the arm for Pfizer’s biosimilars

12 February 2015 Business

news image

$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new de...

Most Read

Flushing advice is flawed

24 August 2015 Research

news image

Protocols to restore contaminated water supplies are not based on science

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

New drug treatment for alcoholism shows promise in animal studies

24 August 2015 Research

news image

Compounds that target a receptor in the brain appear less addictive with fewer negative side-effects than existing drugs

Exploiting the data mine

13 August 2015 Feature

news image

Chemists must embrace open data to allow us to collectively get the best out of the masses of new knowledge we unearth, repor...